What is it about?

We summarize the pivotal trials in the field of metastatic melanoma, as well as the available studies on quality of life and psycho social outcome in the field of melanoma.

Featured Image

Why is it important?

Since the introduction of immune therapy in 2012, a growing number of metastatic melanoma patients achieve long-term survival. However very little is known about possible long- term effects of immune-related adverse events, psycho-social wellbeing, neuro-cognitive function and quality of life in this novel population of advanced melanoma survivors treated with immune checkpoint inhibitors. We believe that our review will be of great clinical relevance for clinicians, as it highlights all aspects that are of relevance to this new field of survivorship.


I hope this article points out that metastatic melanoma survivors might be at risk to suffer from psycho-social issues and that additional studies are necessary to assess their care needs.

Anne Rogiers
CHU Brugmann, Brussels, Belgium

Read the Original

This page is a summary of: Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors, Journal of Oncology, April 2019, Hindawi Publishing Corporation,
DOI: 10.1155/2019/5269062.
You can read the full text:

Open access logo


The following have contributed to this page